The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease
October 3, 2017 Mobile Devices in Clinical Trials for Neurological Diseases: CDISC Standards Development March 10, 2017 Pointe Hilton Tapatio Cliffs Resort | Phoenix, AZ Overview and Objectives The Coalition Against Major Diseas
Critical Path for Parkinson’s Consortium achieves regulatory support in Europe for use of imaging biomarker in Parkinson’s disease clinical trials Oct 10, 2016 Critical Path for Parkinson’s Consortium achieves regulatory support in Europe for use of imaging
Critical Path for Parkinson’s: Regulatory Path to Enable Targeting the Right Patients in Clinical Trials of Early Stages of Parkinson’s Disease
The Michael J. Fox Foundation for Parkinson’s Research Joins Multinational Critical Path for Parkinson’s Consortium May 19, 2016 The Michael J. Fox Foundation for Parkinson’s Research Joins Multinational Critical Path for Parkinso
Parkinson’s UK Announces Major Pharma Companies Sign Up to CPP Major pharma companies sign up to groundbreaking Parkinson’s consortium Seven of the world’s largest pharmaceutical companies
Parkinson’s UK and Critical Path Institute Launch the Critical Path for Parkinson’s (CPP) Consortium October 14, 2015 Parkinson’s UK and Critical Path Institute Launch the Critical Path for Parkinson’s (CPP) Consortium Data fro
Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease Stephenson D, Hu MT, Romero K, Breen K, Burn D, Ben-Shlomo Y, Bhattaram A, Isaac M, Venuto C, Kubota K, Little MA, Friend S, Loves
Critical Path Institute Secures Regulatory Support For Parkinson’s And Alzheimer’s Disease Biomarkers April 27, 2015 Critical Path Institute Secures Regulatory Support For Parkinson’s And Alzheimer’s Disease Biomarkers F
